Free Trial
→ Is Nvidia about to Trigger Another 150X Opportunity? (From InvestorPlace) (Ad)tc pixel
NASDAQ:MRUS

Merus Q3 2025 Earnings Report

Merus logo
$94.29 +0.14 (+0.15%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$93.86 -0.44 (-0.46%)
As of 10/3/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Merus EPS Results

Actual EPS
N/A
Consensus EPS
-$1.20
Beat/Miss
N/A
One Year Ago EPS
N/A

Merus Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.73 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Merus Announcement Details

Quarter
Q3 2025
Date
10/30/2025
Time
Before Market Opens
Conference Call Date
Friday, October 31, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Merus Earnings Headlines

HC Wainwright Predicts Merus' FY2027 Earnings (NASDAQ:MRUS)
October 4 at 2:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30357714
Traders Purchase Large Volume of Put Options on Merus (NASDAQ:MRUS)
October 4 at 2:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30357552
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
October 4 at 2:00 AM  |  Brownstone Research (Ad)
FY2027 Earnings Forecast for Merus Issued By William Blair
October 3 at 3:39 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30356700
Merus (NASDAQ:MRUS) Cut to "Equal Weight" at Barclays
October 3 at 2:19 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30356146
Guggenheim Reiterates Neutral Rating for Merus (NASDAQ:MRUS)
October 2 at 5:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30355555
See More Merus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merus and other key companies, straight to your email.

About Merus

Merus (NASDAQ:MRUS) NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach.

Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem.

Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.

View Merus Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles